Allist(SH:688578)2025-02-25 07:55Financial Performance - The total operating revenue for 2024 reached RMB 355,777.79 million, representing a year-on-year increase of 76.29%[2] - The net profit attributable to the parent company was RMB 142,412.42 million, up 121.08% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was RMB 135,151.86 million, up 122.96% year-on-year[2] - The basic earnings per share increased to RMB 3.16, reflecting a growth of 120.98% year-on-year[2] Product Performance - The core product, Fumetinib Mesylate Tablets (brand name "Aifusha®"), generated sales revenue of RMB 350,559.86 million during the reporting period[5] Asset and Equity Growth - Total assets at the end of the reporting period were RMB 591,407.90 million, a 35.13% increase from the beginning of the period[5] - The equity attributable to the parent company increased by 32.52% to RMB 527,713.87 million[5] - The increase in total assets and equity was primarily driven by the substantial growth in operating revenue and profits[8] Return on Investment - The weighted average return on net assets rose to 30.74%, an increase of 12.77 percentage points[2] Cost Management - The company implemented cost control measures that contributed to significant profit growth during the reporting period[6]